文献速递前列腺癌

局限性前列腺癌:根治性与局灶治疗的6年肿瘤控制倾向评分加权比较

Conventional radical versus focal treatment for localised prostate cancer: a propensity score weighted comparison of 6-year tumour control.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2021-05-01

本研究基于荷兰和英国多中心登记数据,纳入830例根治性治疗(放疗440例、前列腺切除术390例)和530例局灶治疗患者,采用倾向评分加权比较6年无失败生存(FFS)和总生存(OS)。结果显示根治性治疗6年加权FFS为80.3%(95%CI 73.9-87.3),局灶治疗为72.8%(95%CI 66.8-79.8),差异无统计学意义(p=0.1);但根治性治疗6年加权OS显著更低(93.4% vs 97.5%,p=0.02)。

要点

  • 6年无失败生存根治性治疗80.3% vs 局灶治疗72.8%,差异无统计学意义(p=0.1)。
  • 6年总生存根治性治疗93.4%显著低于局灶治疗97.5%(p=0.02)。
  • 三组分析中,局灶和LRP患者治疗失败风险高于EBRT(p<0.001),但EBRT死亡风险高于局灶(p=0.008)。

核心结论

  • 在队列分析局限性下,局灶治疗与根治性治疗在6年肿瘤控制方面无临床相关差异。

研究设计与样本

  • 多中心登记数据的倾向评分加权比较,纳入830例根治性治疗(440例放疗、390例前列腺切除术)和530例局灶治疗(冷冻、高强度聚焦超声或高剂量率近距离放疗)患者,治疗时间2005-2018年。
  • 纳入标准为PSA<20 ng/mL、Gleason评分≤7、T分期≤T2c。
  • 中位随访时间根治性治疗组55(28-83)个月,局灶治疗组62(42-83)个月。

主要发现

  • 基线时根治性治疗患者PSA更高(10.3 vs 7.9),高级别疾病比例更高(31% ISUP 3 vs 11%)。
  • 倾向评分加权后所有协变量均衡(SMD<0.1)。
  • 6年加权FFS根治性治疗80.3%(95%CI 73.9-87.3) vs 局灶治疗72.8%(95%CI 66.8-79.8),p=0.1。
  • 6年加权OS根治性治疗93.4%(95%CI 90.1-95.2) vs 局灶治疗97.5%(95%CI 94-99.9),p=0.02。
  • 三组分析中,局灶和LRP患者治疗失败风险高于EBRT(p<0.001),EBRT死亡风险高于局灶(p=0.008)。

临床怎么用

  • 对于符合纳入标准(PSA<20 ng/mL、Gleason≤7、T≤T2c)的局限性前列腺癌患者,局灶治疗可作为保留器官的替代选择,6年肿瘤控制与根治性治疗无临床相关差异。
  • 需权衡根治性治疗(尤其是EBRT)可能增加的死亡风险与局灶治疗的治疗失败风险。

局限性

  • 基于队列分析,可能存在残余混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: For localised prostate cancer, focal therapy offers an organ-sparing alternative to radical treatments (radiotherapy or prostatectomy). Currently, there is no randomised comparative effectiveness data evaluating cancer control of both strategies. METHODS: Following the eligibility criteria PSA < 20 ng/mL, Gleason score ≤ 7 and T-stage ≤ T2c, we included 830 radical (440 radiotherapy, 390 prostatectomy) and 530 focal therapy (cryotherapy, high-intensity focused ultrasound or high-dose-rate brachytherapy) patients treated between 2005 and 2018 from multicentre registries in the Netherlands and the UK. A propensity score weighted (PSW) analysis was performed to compare failure-free survival (FFS), with failure defined as salvage treatment, metastatic disease, systemic treatment (androgen deprivation therapy or chemotherapy), or progression to watchful waiting. The secondary outcome was overall survival (OS). Median (IQR) follow-up in each cohort was 55 (28-83) and 62 (42-83) months, respectively. RESULTS: At baseline, radical patients had higher PSA (10.3 versus 7.9) and higher-grade disease (31% ISUP 3 versus 11%) compared to focal patients. After PSW, all covariates were balanced (SMD < 0.1). 6-year weighted FFS was higher after radical therapy (80.3%, 95% CI 73.9-87.3) than after focal therapy (72.8%, 95% CI 66.8-79.8) although not statistically significant (p = 0.1). 6-year weighted OS was significantly lower after radical therapy (93.4%, 95% CI 90.1-95.2 versus 97.5%, 95% CI 94-99.9; p = 0.02). When compared in a three-way analysis, focal and LRP patients had a higher risk of treatment failure than EBRT patients (p < 0.001), but EBRT patients had a higher risk of mortality than focal patients (p = 0.008). CONCLUSIONS: Within the limitations of a cohort-based analysis in which residual confounders are likely to exist, we found no clinically relevant difference in cancer control conferred by focal therapy compared to radical therapy at 6 years.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. van Son MJ, Peters M, Reddy D, et al. Conventional radical versus focal treatment for localised prostate cancer: a propensity score weighted comparison of 6-year tumour control. Prostate Cancer Prostatic Dis. 2021. PMID: 33934114. doi:10.1038/s41391-021-00369-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。